2 Janssen therapies for RRMM earn positive opinion from EU committee
A European Medicines Agency committee has recommended that one…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Next IMF Patient and Family Seminar slated for Aug. 18-19 in LA
The International Myeloma Foundation (IMF) will host its…
Study shows less hospital time for outpatient stem cell transplants
Multiple myeloma patients undergoing a stem cell transplant…
FDA puts CART-ddBCMA Phase 2 trial on hold after patient’s death
The U.S. Food and Drug Administration (FDA) has placed…
Phase 1b trial of STAR-LLD combo for myeloma approved by FDA
The U.S. Food and Drug Administration (FDA) has cleared…
FDA asked to extend Carvykti to myeloma patients after first relapse
Janssen is asking the U.S. Food and…
